Adherence to treatment of latent tuberculosis infection in a clinical population in New York City

被引:72
作者
Li, Jiehui [1 ]
Munsiff, Sonal S. [1 ,2 ]
Tarantino, Tania [1 ]
Dorsinville, Marie [1 ]
机构
[1] New York City Dept Hlth & Mental Hyg, New York, NY 10279 USA
[2] Ctr Dis Control & Prevent, Atlanta, GA USA
关键词
Latent TB infection; Treatment; Tuberculosis prevention; Adherence; RIFAMPIN PREVENTIVE THERAPY; TREATMENT COMPLETION; CONTROLLED-TRIAL; OUTCOMES;
D O I
10.1016/j.ijid.2009.05.007
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Low adherence to treatment of latent tuberculosis infection (TLTBI) diminishes TB prevention efforts. This study examined the treatment completion rate among those who started TLTBI and factors associated with adherence to TLTBI. Methods: Patients who started TLTBI in New York City (NYC) Health Department chest clinics during January 2002 - August 2004 were studied. TLTBI completion rate were described and compared according to patient demographic and clinical characteristics by regimen using univariate analysis and log-binomial regression. Results: A total of 15 035 patients started and 6788 (45.2%) completed TLTBI. Treatment completers were more likely than non-completers to be >= 35 years old (52.5%, adjusted relative risk (aRR) = 1.2, 95% confidence interval (CI) = 1.1, 1.2), contacts to pulmonary TB patients (57.4%, aRR = 1.5, 95% CI = 1.4, 1.7), treated by directly observed preventive therapy (DOPT) (71.4%, aRR = 1.3, 95% CI = 1.2, 1.3), and to have received the rifamycin-based regimen (60.0%, aRR = 1.2, 95% CI = 1.1, 1.3). The completion rate with an isoniazid regimen did not differ between HIV-infected and HIV-uninfected persons. Among those who failed to complete, 3748 (47.8%) failed to return for isoniazid and 59 (14.7%) for rifamycin after the. first month of medication dispensing. Conclusions: Shorter regimen and DOPT increased completion rates for LTBI. Though efforts to improve TLTBI completion need to address all groups, greater focus is needed for persons who are contacts and HIV-infected, as they have higher risk of developing TB. (C) 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:E292 / E297
页数:6
相关论文
共 30 条
[1]  
[Anonymous], 2000, MMWR Recomm Rep, V49, P1
[2]  
[Anonymous], 2000, Healthy People 2010: Understanding and Improving Health
[3]  
*CDCP, 2004, MMWR-MORBID MORTAL W, V53, P37
[4]   A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users [J].
Chaisson, RE ;
Barnes, GL ;
Hackman, J ;
Watkinson, L ;
Kimbrough, L ;
Metha, S ;
Cavalcante, S ;
Moore, RD .
AMERICAN JOURNAL OF MEDICINE, 2001, 110 (08) :610-615
[5]  
Comstock GW, 1999, INT J TUBERC LUNG D, V3, P847
[6]   A controlled comparison of directly observed therapy vs self-administered therapy for active tuberculosis in the urban United States [J].
Davidson, BL .
CHEST, 1998, 114 (05) :1239-1243
[7]   PATIENT NONCOMPLIANCE - DEVIANCE OR REASONED DECISION-MAKING [J].
DONOVAN, JL ;
BLAKE, DR .
SOCIAL SCIENCE & MEDICINE, 1992, 34 (05) :507-513
[8]  
Ferebee SH., 1969, ADV TUBERC RES, V17, P29
[9]  
GLASSROTH J, 1989, CLIN CHEST MED, V10, P365
[10]   THE HUMAN DIMENSION OF TUBERCULOSIS-CONTROL [J].
GRANGE, JM ;
FESTENSTEIN, F .
TUBERCLE AND LUNG DISEASE, 1993, 74 (04) :219-222